Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $43.2052W HIGH $72.69
Volume
1.87 M
Value Traded
240.94 M
Short % Float
4.25%
-0.15%Week
+0.12%1 Month
+2.09%3 Month
+34.57%6 Month
-53.43%5 Year
+43,977.71%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
11.35 B
EPS (TTM)
1.16
P/E Ratio
62.43
Ent. Value
11.09 B
Total Shares
156.82 M
Float Shares
155.96 M
Insiders
0.55%
Institutions
113.84%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
TECH Catalyst Timeline
Dated clinical, regulatory and corporate events for Bio-Techne Corp
Catalyst Timeline
Dated clinical, regulatory & corporate events for Bio-Techne Corp
460Total events
2Upcoming
99Tier-1 (high impact)
2014 to 2027Coverage
Upcoming catalysts 2
Event history 50
▲Corporate ApprovalCorporate
HSR waiting period for Merck KGaA/Bio-Techne transaction expired
▲Product LaunchPost-Market
Launch of expanded R&D Systems AI-Engineered Designer Protein portfolio including FGF-4 Heat Stable, FGF-7 Heat Stable, FGF-8b Heat Stable, IL-3 Heat Stable, IL-15 Hyperactive
●Manufacturing MilestoneCMC / Inspection
Customer Experience Centre opening in Düsseldorf, Germany
◆Oral PresentationPresentation
Bio-Techne to present at Bank of America Securities 2026 Global Healthcare Conference
◆Quarterly UpdateCorporate
Bio-Techne to announce third quarter fiscal 2026 financial results
▲Other Regulator MilestoneEllaEx-US Regulatory
Ella platform receives CE-IVD marking for European Union
▲Product LaunchPost-Market
Launch of Simple Plex Ultra-Sensitive Assays on Ella platform
neurodegenerative diseasesource ↗
◆Oral PresentationPresentation
Bio-Techne to present at 2026 J.P. Morgan Healthcare Conference
▲Partnership / LicenseCorporate
Strategic collaboration between Lunaphore (Bio-Techne brand) and Wyss Center Geneva to develop automated protocol for simultaneous RNA and protein detection in 3D samples
◆Quarterly UpdateCorporate
Bio-Techne to report first quarter fiscal 2026 financial results and host conference call
◆Poster PresentationPresentation
Poster #528 presenting SECOMBIT study data at SITC 2025
melanomasource ↗
▲Partnership / LicenseCorporate
Expanded agreement with Oxford Nanopore Technologies through 2032
▲Fast Track DesignationDesignation
Several large customers received Fast Track Designation from FDA for cell therapy products
●Oral PresentationPresentation
Bio-Techne and Leica Biosystems co-host waterfront reception at NSH
●Oral PresentationPresentation
Bio-Techne showcases spatial biology innovations at NSH Convention
◆Oral PresentationPresentation
Morgan Stanley 23rd Annual Global Healthcare Conference Presentation
▼Program DiscontinuationCorporate
Divestiture of Exosome Diagnostics business including ExoDx Prostate test (EPI)
prostate cancersource ↗
▲Partnership / LicenseCorporate
ScaleReady awards G-Rex Grant to Sidra Medicine for CAR-T cell therapy development
▲Partnership / LicenseCorporate
Bio-Techne and Spear Bio announce strategic partnership to distribute Spear Bio's ultrasensitive immunoassays
▲Partnership / LicenseCorporate
Distribution agreement with USP to sell mAb and AAV reference standards
◆Oral PresentationPresentation
Protein Quantitation Applications to Advance Gene Therapy Development – From Discovery Through Analytical Development
◆Oral PresentationPresentation
Bio-Techne to present at BofA Securities 2025 Health Care Conference
Past FDA Catalysts and PDUFA Decisions
How TECH actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Clinical Trial Results
Readouts, endpoints and source filings for every TECH program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| metastatic melanoma | 2025-11-04 | 42 pre-treatment biopsies, three treatment arms incorporating Immune Checkpoint Blockade (ICB)Read More | AI-Powered Spatial Biology Workflow from Bio-Techne and Nucleai Enables Predictive Biomarker Discovery in Melanoma PatientsRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| HIGGINS JOHN LDirector | Option | 15,940 82,816 held | $0.00 | 09/28/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in TECH
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| IRON TRIANGLE PARTNERS LP | 3.1 % (34.8 %) | 27.49 M | 467.41 K | 86.96% ( 217.41 K) |
TECH Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2027-05-21 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How TECH ranks across every disease it competes in
Competitive Position is a premium feature
See how TECH ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialTECH News
TECHBio-Techne Shareholders Approve Acquisition by Merck KGaA, Darmstadt, Germany
Bio-Techne shareholders have approved the acquisition by Merck KGaA, marking a significant step towards completing the merger. The transaction is expected to provide substantial cash value to shareholders and enhance the capabilities of both companies in life sciences. The acquisition is anticipated to close by late 2026 or early 2027, pending regulatory approvals.
Read more →TECHBio-Techne Opens New Customer Experience Center in Düsseldorf to Accelerate Scientific Discovery and Customer Collaboration
Bio-Techne has inaugurated a new Customer Experience Center in Düsseldorf, Germany, aimed at enhancing collaboration and innovation in the life sciences sector. This facility will serve as a regional hub for researchers and organizations in the DACH and EMEA regions, providing hands-on access to Bio-Techne's technologies and expertise. The center will host workshops and training programs, reinforcing Bio-Techne's commitment to supporting scientific excellence across Europe.
Read more →TECHBio-Techne Achieves Science Based Targets Validation and Reports Significant Progress Toward Climate Goals
Bio-Techne Corporation has made significant strides in its climate goals, achieving validation from the Science Based Targets initiative for its greenhouse gas reduction targets. The company reported a 49% reduction in Scope 1 and 2 emissions year-over-year and transitioned to 100% renewable electricity at its Minneapolis headquarters. Additionally, Bio-Techne aims for 81% of its suppliers to have science-based targets by fiscal year 2030.
Read more →TECHBio-Techne Corrects Dividend Announcement
Bio-Techne Corporation corrected its dividend announcement, stating the shareholder of record date is August 24, 2026, instead of August 17. The company will pay a dividend of $0.08 per share for the quarter ended June 30, 2026, payable on August 28, 2026. All other details of the announcement remain unchanged.
Read more →TECHBio-Techne Declares Dividend
Bio-Techne Corporation announced a quarterly dividend of $0.08 per share for shareholders of record on August 17, 2026. This dividend reflects the company's strong financial performance, having generated over $1.2 billion in net sales in fiscal year 2026. The company, celebrating its 50th anniversary, continues to empower scientific communities globally.
Read more →TECHBio-Techne Releases Fourth Quarter Fiscal 2026 Results
Bio-Techne Corporation reported its financial results for the fourth quarter of fiscal 2026, highlighting a 3% increase in organic revenue and a significant improvement in GAAP EPS. The company is set to be acquired by Merck KGaA for $73 per share, which is anticipated to provide new opportunities for growth. Despite these positives, adjusted EPS saw a slight decline, and overall revenue remained flat for the year.
Read more →TECHBio-Techne Launches Expanded R&D Systems AI-Engineered Designer Protein Portfolio
Bio-Techne Corporation has expanded its R&D Systems AI-Engineered Designer Protein portfolio with new heat-stable and hyperactive proteins. These innovations aim to enhance reproducibility and performance in advanced cell culture and cell therapy workflows. The new proteins are designed to address challenges in scaling cell therapy from discovery to manufacturing, supporting various applications in regenerative medicine.
Read more →TECHBio‑Techne and Refeyn Close Critical Gap in Bispecific Antibody and Biosimilar Characterization
Bio-Techne and Refeyn have launched an innovative integrated workflow for characterizing bispecific antibodies and biosimilars. This new method combines icIEF fractionation with mass photometry, allowing for direct analysis of charge and size variants in a streamlined four-hour process. The technology aims to reduce development risks and accelerate biosimilar manufacturing, addressing challenges in the characterization of complex biotherapeutics.
Read more →TECHBio‑Techne and Refeyn Close Critical Gap in Bispecific Antibody and Biosimilar Characterization Bio‑Techne Corporation (NASDAQ: TECH), a global provider of life science tools, reagents and diagnostic products, and Refeyn, the pioneer in mass...
Bio-Techne Corporation and Refeyn have launched a novel integrated workflow for the characterization of charge and size variants in bispecific antibodies and biosimilars. This new approach combines Bio-Techne's MauriceFlex imaged capillary isoelectric focusing system with Refeyn's TwoMP mass photometry platform. The innovation allows researchers to streamline their characterization process, significantly reducing the time required for analysis. This development is expected to enhance the understanding of complex biotherapeutics, potentially accelerating their development in the market.
Read more →TECH▼ -16.4%on this news
Bio-Techne Declares Dividend Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended...
Bio-Techne Corporation (NASDAQ: TECH) has announced a dividend payment of $0.08 per share for the quarter ending March 31, 2026. This quarterly dividend will be payable on May 29, 2026, to shareholders on record by May 18, 2026. The Board of Directors will consider future dividends on a quarterly basis, highlighting the company's ongoing commitment to shareholder value. Despite this positive development, the company has acknowledged potential risks that could impact its operations and share price.
Read more →TECH▼ -16.4%on this news
Bio-Techne Releases Third Quarter Fiscal 2026 Results
Bio-Techne Corporation reported its third quarter fiscal 2026 results, revealing a 2% decline in revenue to $311.4 million, impacted by prior-year orders and shipment timing. Despite this, GAAP EPS rose to $0.32, and large pharma continued its growth trend. The company remains optimistic about future demand as funding activity stabilizes.
Read more →TECHBio-Techne to Present at the Bank of America Securities 2026 Global Healthcare Conference
Bio-Techne Corporation announced that CEO Kim Kelderman will present at the Bank of America Securities 2026 Global Healthcare Conference on May 12, 2026. The presentation will be accessible via a live webcast on the company's Investor Relations website. Bio-Techne has a rich history of 50 years in the life sciences sector and operates globally.
Read more →TECHBio-Techne Introduces Streamlined Brand Architecture to Help Customers Navigate Solutions Faster and With Greater Clarity
Bio-Techne Corporation has introduced a streamlined brand architecture to improve customer navigation of its life science solutions. The new structure organizes products into three focused brands: R&D Systems, Bio-Techne Spatial, and Bio-Techne Diagnostics, aligning with the progression of scientific research. This initiative aims to empower scientists and clinicians by providing easier access to essential tools and technologies.
Read more →TECHBio-Techne to Host Conference Call on May 6, 2026, to Announce Third Quarter Fiscal 2026 Financial Results
Bio-Techne Corporation announced a conference call scheduled for May 6, 2026, to discuss its third quarter fiscal 2026 financial results. The call will be accessible via dial-in and webcast, with a replay available for those unable to attend live. The company continues to thrive in the life sciences sector, generating significant revenue.
Read more →TECHBio-Techne Advances Spatial Biology with Modular Expansion of COMET™ Suite
Bio-Techne Corporation has expanded its COMET solution portfolio by introducing SPYRE Focus Panels and SPYRE Amplification Kits. These innovations aim to enhance the modular, automated spatial biology workflow, providing researchers with greater flexibility and sensitivity. The new features in HORIZON Image Analysis Software further support these advancements, facilitating deeper biological insights from tissue samples.
Read more →TECH▲ +5.2%on this news
Bio-Techne to Present at Upcoming Investor Conferences
Bio-Techne Corporation has announced its participation in two upcoming investor conferences. The TD Cowen 46th Annual Health Care Conference is scheduled for March 3, 2026, and the Leerink Partners Global Healthcare Conference will take place on March 10, 2026. Live webcasts of these presentations will be available on the company's Investor Relations website.
Read more →TECHBio-Techne's Ella Platform Achieves CE-IVD Marking Expanding Access to Rapid, Cartridge‑Based Immunoassays for European Clinical Laboratories
Bio-Techne Corporation's Ella platform has received CE-IVD marking, allowing its sale in the European Union. This compact, cartridge-based immunoassay system provides rapid and accurate biomarker results, enhancing clinical workflows. The certification enables European laboratories to utilize Ella for in-house test development and clinical trials, supporting precision medicine initiatives.
Read more →TECHBio-Techne Announces Changes to its Leadership Team
Bio-Techne Corporation announced a leadership change, with Dr. Matt McManus transitioning from his role as President of the Diagnostics and Spatial Biology Segment effective March 1, 2026. Steve Crouse, previously Senior Vice President of the Analytical Solutions Division, will take over as President. The transition aims to ensure continuity and leverage Crouse's extensive experience in the life sciences sector.
Read more →TECH▲ +6.3%on this news
Bio-Techne Releases Second Quarter Fiscal 2026 Results
Bio-Techne Corporation reported its financial results for Q2 FY2026, highlighting double-digit growth in large pharma for the fourth consecutive quarter. The company experienced stabilization in its U.S. academic market and growth in Asia. Despite flat net sales year-over-year, adjusted earnings per share increased, reflecting ongoing profitability initiatives. The company celebrates its 50th anniversary in 2026, emphasizing its commitment to innovation.
Read more →About Bio-Techne Corp
Headquarters614 MCKINLEY PLACE NE, MINNEAPOLIS, MN
BIOPHARMAWATCH ELITE PLUS
Trade the next TECH catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime